A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Anti-viral Efficacy of Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
Latest Information Update: 08 Feb 2023
At a glance
- Drugs Masitinib (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors AB Science
- 03 Feb 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 03 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 14 Sep 2022 According to a AB Science media release, the company has announced continuation of the trial, following positive recommendation of the Data and Safety Monitoring Board (DSMB).